Caricamento...

Selpercatinib: First Approval

Selpercatinib (RETEVMO™) is a receptor tyrosine kinase RET (rearranged during transfection) inhibitor being developed by Loxo Oncology for the treatment of cancers harbouring RET alterations. Based on results from the phase I/II LIBRETTO-001 trial, selpercatinib was recently approved by the US FDA f...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Drugs
Autore principale: Markham, Anthony
Natura: Artigo
Lingua:Inglês
Pubblicazione: Springer International Publishing 2020
Soggetti:
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7716849/
https://ncbi.nlm.nih.gov/pubmed/32557397
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40265-020-01343-7
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !